PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-18.36%
Revenue decline while VET shows 11.32% growth. Joel Greenblatt would examine competitive position erosion.
6.33%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
-39.33%
Gross profit decline while VET shows 23.15% growth. Joel Greenblatt would examine competitive position.
-25.68%
Margin decline while VET shows 10.63% expansion. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
41.18%
G&A growth above 1.5x VET's 8.28%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-10.88%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-7.01%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
1.66%
Total costs growth while VET reduces costs. John Neff would investigate differences.
10.19%
Interest expense growth while VET reduces costs. John Neff would investigate differences.
-0.31%
D&A reduction while VET shows 3.84% growth. Joel Greenblatt would examine efficiency.
-41.75%
EBITDA decline while VET shows 39.67% growth. Joel Greenblatt would examine position.
-24.33%
EBITDA margin decline while VET shows 25.47% growth. Joel Greenblatt would examine position.
-66.67%
Operating income decline while VET shows 182.07% growth. Joel Greenblatt would examine position.
-59.17%
Operating margin decline while VET shows 153.39% growth. Joel Greenblatt would examine position.
-74.14%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-74.24%
Pre-tax income decline while VET shows 208.83% growth. Joel Greenblatt would examine position.
-68.44%
Pre-tax margin decline while VET shows 177.43% growth. Joel Greenblatt would examine position.
-71.13%
Tax expense reduction while VET shows 274.19% growth. Joel Greenblatt would examine advantage.
-75.16%
Net income decline while VET shows 25.13% growth. Joel Greenblatt would examine position.
-69.57%
Net margin decline while VET shows 12.40% growth. Joel Greenblatt would examine position.
-75.00%
EPS decline while VET shows 25.00% growth. Joel Greenblatt would examine position.
-75.00%
Diluted EPS decline while VET shows 25.00% growth. Joel Greenblatt would examine position.
0.07%
Share count reduction exceeding 1.5x VET's 0.83%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.